GlassScriptPhysician profile
Lixuan Li
NPI 1437629557
$8,221.48
in general payments reported to CMS, 2019-2025
29 companies · $6,503 in 2025
The $6,503 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $104 · 2024: $1,614 · 2025: $6,503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,117.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,137.30 | 2024-2025 | Repatha, Evenity, Otezla |
| Abbvie INC. | $991.90 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $677.98 | 2024-2025 | Ofev, Jardiance |
| Madrigal Pharmaceuticals | $570.15 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $552.17 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $512.98 | 2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $496.99 | 2024-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $448.69 | 2024-2025 | Dupixent |
| Ardelyx, INC. | $422.84 | 2024-2025 | Ibsrela |
| Viatris Specialty LLC | $376.97 | 2025 | Yupelri |
| Genzyme Corporation | $288.59 | 2024-2025 | |
| Insmed, INC. | $256.65 | 2024-2025 | Arikayce, Brinsupri |
| Lilly USA, LLC | $238.07 | 2025 | Mounjaro, Zepbound |
| Aimmune Therapeutics, INC. | $188.03 | 2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $150.00 | 2025 | Iqirvo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $126.45 | 2024-2025 | Verquvo |
| Ucb, INC. | $117.59 | 2025 | Bimzelx |
| Ibsa Pharma INC. | $104.17 | 2022 | |
| Exact Sciences Corporation | $88.09 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $87.72 | 2024 | |
| Gilead Sciences, INC. | $75.70 | 2025 | |
| Novo Nordisk INC | $57.37 | 2024 | Rybelsus, Ozempic |
| Intra-Sana Laboratories | $49.35 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Mylan Specialty L.P. | $49.20 | 2024 | Yupelri |
| Axsome Therapeutics, INC. | $48.82 | 2025 | Symbravo |
| Electromed, INC. | $30.19 | 2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $30.00 | 2025 | Opsumit |
| Agepha Pharma Fz LLC | $26.84 | 2025 | Lodoco |
| Esperion Therapeutics, INC. | $20.68 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lixuan Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.